下一个

自动播放

The future of CTCL therapy

4 意见 • 08/09/23
分享
嵌入
administrator
administrator
订户
0

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, suggests how the therapeutic landscape of cutaneous T-cell lymphoma (CTCL) may evolve in the future, with the development of novel monoclonal antibodies, oncogenic peptides, and agents targeting overactivated signaling pathways in CTCL. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放